Your session is about to expire
← Back to Search
Cannabinoid
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Phase 1
Waitlist Available
Research Sponsored by Receptor Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 minutes, assessed at visit 2 and visit 3
Summary
This trial is testing an inhaled CBD powder to help adults with social anxiety disorder feel less anxious during public speaking. The treatment works by calming the brain. The study will check if this method is safe and effective over several weeks. Cannabidiol (CBD) has been shown to reduce anxiety in various settings, including public speaking and treatment-resistant anxiety disorders.
Eligible Conditions
- Social Anxiety Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 minutes, assessed at visit 2 and visit 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 minutes, assessed at visit 2 and visit 3
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence and severity of adverse events
Secondary study objectives
Change in CGI
Change in subject-reported anxiety
Other study objectives
Changes in blood pressure in subjects with SAD
Changes in pulse rate in subjects with SAD
Changes in respiratory rate in subjects with SAD
Trial Design
3Treatment groups
Experimental Treatment
Group I: placeboExperimental Treatment1 Intervention
placebo inhaled dry powder
Group II: Low dose RLS103Experimental Treatment1 Intervention
3 mg CBD inhaled dry powder
Group III: High dose RLS103Experimental Treatment1 Intervention
6 mg CBD inhaled dry powder
Find a Location
Who is running the clinical trial?
Receptor Life SciencesLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled